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Previewsversus NOD2 allow the innate immune
system to recognize biochemical differ-
ences between Gram-positive and Gram-
negative bacteria, several other innate
receptors recognize conserved motifs,
e.g., DNA by TLR9 and RNA by RIG-I heli-
case.
The capacity of the innate immune
system to distinguish biochemical differ-
ences between Gram-positive and Gram-
negative bacteria does not appear to
result in distinct functional responses.
Activation of TLR2-TLR1 and TLR2-
TLR6 induces innate immune pathways
required for host defense against micro-
bial pathogens including cytokine release
and dendritic cell and macrophage differ-
entiation (Krutzik et al., 2005), as well as
microbicidal activity (Liu et al., 2006)
(Figure 1). Therefore, the function of the
different TLR2 heterodimers is to enable
recognition of bacteria with different cell
envelopes, but that once triggered, the
immunologic mechanisms appear to acti-
vate the same pathways. The elegant
recognition mechanisms by which TLRs
can distinguish lipoproteins provides a
new impetus to search for differences in
the subsequent innate immune response.
The ability of TLR2 to mediate the
recognition and immune response to
various nonpeptide ligands, including
lipoteichoic acid, is still controversial
and thought by some to be the result ofcontamination of preparations with lipo-
proteins, as extensively discussed by
Kang et al. in the Supplemental Data
(Kang et al., 2009). Nevertheless, Kang
et al. provide evidence that lipoteichoic
acid from Streptococcus pneumoniae
binds to TLR2, with the lipid chains in-
serted into the TLR2 hydrophobic pocket.
They also provide evidence that the polar
head groups of TLR2 ligands are critical
for heterodimer formation. These studies
indicate that such nonpeptide ligands
can bind to TLR2 but do not resolve
the issue as to whether they, under
physiologic conditions, activate cellular
responses. Clearly, more research into
this area is warranted to define the
universe of natural TLR2 ligands that can
trigger host innate immune responses.
In summary, the innate immune system
is encoded to distinguish biochemical
differences between Gram-positive and
Gram-negative bacteria. In particular, the
laboratory of Jie-Oh Lee has provided
clear evidence that TLR2 has 20/20 vision
for lipoproteins, the heterodimerization of
TLR2-TLR1 and TLR2-TLR6 heterodimers
forms different lipid-binding pockets that
distinguish triacylated from diacylated
lipopeptides (Jin et al., 2007; Kang et al.,
2009). Although TLR2 has perfect vision
to distinguish distinct lipoproteins, the
subsequent immune responses appear
to be identical carbon copies.Immunity 31, DREFERENCES
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The ability of a single T cell to recognize the diverse peptides it encounters is based on T cell receptor
crossreactivity. In this issue of Immunity, Macdonald et al. (2009) and Borbulevych et al. (2009) provide
new insights into the structural principles underlying this fundamental property of T cells.Given the vast numbers of clonotypically
unique T cell receptors (TCRs) that can
be generated by combinatorial diversifi-cation and imprecise joining of gene
segments, it was initially believed that
the immune system might be capable ofgenerating a unique TCR for almost every
antigenic peptide. However, subsequent
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Figure 1. Mechanisms for an Individual TCR to Cross-react with Different Peptide-MHC
Ligands
The top row, from left to right: Cross-reactivity through induced fit. A conformationally flexible binding site
enables a single TCR to accommodate different peptide-MHC ligands without altering the overall docking
orientation. TCR is orange; peptides are red or purple; and MHCmolecules are green or blue. Cross-reac-
tivity through differential TCR docking. The same TCR binds different peptide-MHC ligands using different
docking orientations. Crossreactivity through structural degeneracy. Suboptimal complementarity
between peptide and TCR can be improved by variations in the peptide. The bottom row, from left to right:
Cross-reactivity through molecular mimicry. Different peptide-MHC ligands can form very similar
interfaces with the crossreactive TCR if the ligands are close structural mimics. Cross-reactivity through
antigen-dependent tuning of peptide-MHC flexibility. Conformational dynamics in the peptide-MHC
ligand allow structural reorganization upon TCR binding (see text for details).
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Previewsshowed that there are far more potentially
immunogenic peptides in the environ-
ment of an individual than the number of
T cells the individual has at any given
moment (Mason, 1998). Moreover, in
order to differentiate in the thymus and,
once mature, to achieve maximum
sensitivity upon recognition of foreign
peptides, T cells must also recognize,
with low affinity, MHC molecules bearing
peptides derived from self-proteins (Starr
et al., 2003). Accordingly, the concept of
TCR cross-reactivity (alternately referred
to in the immunological literature as
degeneracy or alloreactivity) has been
evoked as a means for expanding the
effective size of the TCR repertoire.
Because of the importance of TCR
cross-reactivity in immune surveillance
and thymic selection, the molecular
mechanisms underlying the intrinsic
ability of TCRs to recognize a broad range
self- and foreign peptide-MHC ligands850 Immunity 31, December 18, 2009 ª2009has been the subject of much investiga-
tion. With the studies of Macdonald et al.
(2009) and Borbulevych et al. (2009) in
this issue of Immunity, five conceptually
distinct mechanisms have now been
identified that, taken together, largely
explain TCR cross-reactivity at the atomic
level (Figure 1). These mechanisms may
be summarized as follows.
Mechanism 1: Induced Fit
Structural adjustments in the TCR bind-
ing site may allow a single receptor to
recognize different peptide-MHC ligands
while maintaining the same overall
docking orientation. An example of in-
ducedfit is providedbyTCRBM3.3,which
recognizes three distinct peptides bound
to H-2Kb (Mazza et al., 2007). Comparison
of the corresponding BM3.3-peptide-H-
2Kb structures showed that cross-reac-
tivity is achieved through changes in the
conformation of the flexible complemen-Elsevier Inc.tarity-determining region (CDR) loops,
which permit the TCR to reconfigure its
binding site to accommodate different
peptide-MHC ligands. Typically, the larg-
est shifts are observed in the randomly
generated CDR3 loops, with the germline-
encoded CDR1 and CDR2 loops under-
going relatively minor reorganizations.
Mechanism 2: Differential TCR
Docking
In this case, the same TCR engages
different peptide-MHC ligands via dis-
parate docking orientations, without
recourse to molecular mimicry. Thus, the
alloreactive TCR 2C employs two very
different binding modes to recognize
a self ligand (QL9-H-2Ld) compared to
a foreign ligand (dEV8-H-2Kb) (Colf et al.,
2007). Because of a global repositioning
of the TCR on the surface of these ligands,
2C forms unique interatomic contacts
with both shared and polymorphic resi-
dues of Ld and Kb, as well as with the
unrelated peptide antigens QL9 and
dEV8. More generally, this study demon-
strated that a particular receptor need
not utilize the same binding strategy to
cross-react with ligands possessing sub-




TCR cross-reactivity can also result from
a paucity of specific interactions with
peptide-MHC. An example of structural
degeneracy is provided by autoimmune
TCR 3A6, which recognizes a self-
peptide from myelin basic protein (MBP)
presented by HLA-DR2a, as well as
numerous other peptides that are far
more stimulatory than MBP itself (Li
et al., 2005). Examination of the 3A6-
MBP-HLA-DR2a interface revealed a total
absence of hydrogen bonds or salt
bridges between the TCR and peptide,
as well as poor fit. Such structural degen-
eracy introduces a degree of tolerance to
recognition of peptides bearing substitu-
tions in TCR-contacting positions, some
of which also improve shape and chemi-
cal complementarity with TCR, thereby
resulting in cross-reactivity.
Mechanism 4: Molecular Mimicry
Although molecular mimicry, whereby
ligands share key structural and chemical
features, was among the first
Immunity
Previewsmechanisms proposed to explain TCR
cross-reactivity, clear structural evidence
for molecular mimicry, in the form of
complexes between one receptor and
multiple ligands, has proven elusive.
Macdonald et al. (2009) have now pro-
vided such evidence. Thus, TCR LC13
recognizes an immunodominant epitope
of Epstein-Barr virus restricted by self
HLA-B*0801, but also cross-reacts with
two different allopeptides bound to
HLA-B*4402 and HLA-B*4405. Crystal
structure determinations of these cross-
reactive complexes revealed that LC13
engages the allogeneic ligands with the
same overall docking topology as the viral
ligand, despite the disparate sequences
of the allo- and viral peptides. All three
complexes are characterized by very
similar interactions between LC13 and
the C-terminal (P6–P8) region of the
peptides, which is critical for recognition
by this TCR. Specifically, the C-terminal
residues of both allopeptides include an
aromatic side chain at P7 (phenylalanine
or tryptophan), a feature also present in
the viral peptide (P7 Tyr), that protrudes
into a central pocket of the TCR binding-
site and is essential for recognition. By
preserving key interactions with residue
P7, as well as with nonpolymorphic resi-
dues of the HLA-B*0801, HLA-B*4402,
and HLA-B*4405 heavy chains, LC13 is
able to recognize both viral and allogeneic
ligands via molecular mimicry.
In a related study, Harkiolaki et al.
(2009) showed that the autoimmune TCR
Ob.1A12, which recognizes a self-peptide
from MBP bound to HLA-DR2b, also
recognizes a naturally processed peptide
from Escherichia coli. This cross-reac-
tivity, which induced a multiple sclerosis-
like disease in humanized mice, is prob-
ably attributable to structural mimicry of
a binding hotspot shared by the microbial
and self peptides.
Mechanism 5: Antigen-Dependent
Tuning of Peptide-MHC Flexibility
By examining recognition of two similar
HLA-A2-restricted peptides (Tax from
HLTV-1 and Tel1p from S. cerevisiae)
by TCR A6, Borbulevych et al. (2009)
have discovered a previously unsus-
pected mechanism for TCR cross-reac-
tivity, whereby conformational flexibility
in peptide-MHC allows recognition of
different ligands by the same TCR.
Because unligated Tax-HLA-A2 andTel1p-HLA-A2 share nearly identical
3D structures (i.e., are almost perfect
mimics), it was anticipated that simple
molecular mimicry, as described above,
would readily account for cross-reactivity
with TCR A6. Surprisingly, however,
Tax-HLA-A2 and Tel1p-HLA-A2 form
substantially different interfaces with
A6 in the corresponding complexes.
Whereas recognition of Tax-HLA-A2 pro-
ceeds without substantial adjustments in
the ligand, recognition of Tel1p-HLA-A2
is associated with large conformational
differences in both the peptide and MHC,
resulting in altered interactions with TCR.
For example, residue P5 Tyr of Tax main-
tains the same conformation in the free
versus bound ligand and occupies a
pocket between the CDR3a and CDR3b
loops of A6. By contrast, P5 Tyr of
Tel1p is displaced from its unbound
conformation in the complex with A6 and
points toward the HLA-A2 a2 helix. In
addition, TCR recognition of Tel1p-HLA-
A2 involves a substantial structural alter-
ation in the MHC molecule that serves to
accommodate changes in Tel1p.
Borbulevych et al. (2009) propose that
differing levels of ligand flexibility can
explain the structural differences in the
peptide and HLA-A2 molecule observed
upon A6 recognition of Tax and Tel1p
and that these peptides differentially
tune the dynamic properties of HLA-A2
(Figure 1). In support of this idea, fluores-
cence anisotropy measurements and
molecular dynamics simulations indicate
that unligated Tel1p-HLA-A2 is intrinsi-
cally more flexible than unligated Tax-
HLA-A2. Hence, cross-reactivity in this
case appears to be based on conforma-
tional selection by TCR of an alternative
conformation of peptide-MHC that is in
dynamic equilibrium with an ensemble of
pre-existing isomers, as observed for
other protein-protein interactions, includ-
ing antigen-antibody reactions (James
et al., 2003; Lange et al., 2008).
Concluding Remarks
Although we have, for the sake of conve-
nience, presented TCR crossreactivity as
arising from five distinct mechanisms,
it would be simplistic to pigeonhole
individual cases of cross-reactivity on
the basis of rigid classifications. Rather,
a given TCR may employ various combi-
nations of these strategies to increase
the diversity of peptide-MHC ligands itImmunity 31, Dcan recognize. For instance, the CDR
loops of TCR LC13 undergo substantial
induced-fit movements upon binding allo-
geneic ligands that mimic viral ligands
(Macdonald et al., 2009). Conformational
changes also occur in the CDRs of TCR
2C as it engages QL9-H-2Ld and dEV8-
H-2Kb through different docking modes
(Colf et al., 2007). Conversely, binding of
TCR 3A6 to MBP-HLA-DR2a induces
adjustments in both peptide and MHC
that serve to improve shape complemen-
tarity at the structurally degenerate inter-
face with TCR (Li et al., 2005). Hence,
TCR cross-reactivity is the product of a
complex interplay among diverse binding
strategies, whereby individual receptors
utilize different combinations of strategies
to functionally expand the TCR repertoire
for thymic selection and peripheral
surveillance. Whether we have now fully
documented the entire range of strategies
TCRs employ to achieve cross-reactivity,
as well as the relative importance of
particular strategies, will undoubtedly be
topics for future investigation.REFERENCES
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